Trial reportDrug design, development and therapy2026
The Satisfactory Analgesia and Minimal Emesis of Elderly Patients After Thoracoscopic Lung Surgery: Oliceridine versus Sufentanil in a Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Statistical Issues in the Oliceridine versus Sufentanil Trial for Elderly Thoracoscopic Surgery [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare oliceridine with sufentanil for the proportion of elderly patients achieving satisfactory analgesia with minimal emesis (SAME) after thoracoscopic lung surgery. Methods: This prospective, double-blind, randomized controlled trial enrolled elderly patients aged 65-80 years scheduled for thoracoscopic lung surgery to receive patient-controlled intravenous analgesia with either oliceridine or sufentanil. The primary outcome was the proportion of patients achieving SAME within the first 3 postoperative days, defined as a daily average coughing numerical rating scale (NRS) pain score < 4 and daily highest postoperative nausea and vomiting (PONV) score < 2. The secondary outcomes included NRS pain scores, rescue analgesia, 15-item Quality of Recovery (QoR-15) scores, safety outcomes, time to ambulation, and postoperative length of stay. Results: Among the 247 patients analyzed, oliceridine was associated with a higher proportion of patients achieving the SAME endpoint within the first 3 postoperative days compared with sufentanil (46.3% vs 32.3%; Conclusion: Oliceridine, compared with sufentanil for postoperative analgesia, increased the proportion of achieving SAME within the first 3 PODs, provided better analgesia, and improved postoperative recovery quality with comparable safety outcomes for elderly patients undergoing thoracoscopic lung surgery. Trial Registration: www.chictr.org.cn, ChiCTR2500102213.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.